Cellectis S.A. — FY2020 Form 20-F
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter filing. Financial statements are consolidated, prepared under IFRS, and presented in U.S. dollars.
Business context
Cellectis is a clinical-stage gene-editing and cell-therapy company developing allogeneic CAR T-cell candidates. It also consolidates Calyxt, a majority-owned gene-edited plant technology business; Cellectis held 64.7% of Calyxt at year-end. Cellectis had no approved therapeutic products or therapeutic product sales. Therapeutics revenue depended primarily on licensing and collaboration arrangements.
Financial performance and liquidity
| Metric (USD millions, except per-share data) | 2020 | 2019 |
|---|---|---|
| Revenue | 73.9 | 15.2 |
| Other income, mainly French research tax credits | 8.5 | 7.8 |
| Total revenue and other income | 82.5 | 23.0 |
| Cost of revenue | 36.3 | 11.4 |
| Research and development expense | 87.0 | 92.0 |
| Selling, general and administrative expense | 44.2 | 43.0 |
| Operating loss | 85.4 | 123.6 |
| Net loss | 97.5 | 115.2 |
| Net loss attributable to Cellectis shareholders | 81.1 | 102.1 |
| Basic and diluted loss per share | $1.91 | $2.41 |
| Operating cash used | 80.3 | 69.1 |
Revenue increased 386.8%, principally reflecting the Servier agreement amendment: Cellectis recognized a $28.5 million upfront payment and previously deferred amounts when rights were expanded and certain programs were abandoned. The filing reports recognition of deferred amounts as $19.4 million in its revenue discussion and $20.3 million in its management discussion; investors should reconcile these disclosures. Calyxt revenue rose to $22.9 million from $7.3 million, mainly from high-oleic soybean products.
Net loss narrowed by $17.7 million, despite higher cost of revenue and a negative financial result. The operating loss improved by $38.1 million. No meaningful consolidated margin comparison is provided; revenue includes licensing and agricultural product sales with different economics.
At year-end, cash and cash equivalents were $241.1 million and current financial assets were $27.1 million, for $268.2 million combined. The filing separately reports $5.3 million of long-term restricted cash. Total assets were $469.5 million and equity was $308.8 million. Financial liabilities were $111.3 million, including $82.5 million in lease debt and a $22.7 million French state-guaranteed loan; these are not equivalent to conventional funded debt alone. Investing cash outflow was $54.3 million, including $45.7 million of property and equipment purchases. Financing cash inflow was $27.3 million, largely from loans and Calyxt’s share offering.
Management estimated available resources would fund Cellectis and Calyxt into late 2022, based on expected operating cash flows, collaboration payments, government funding, and Calyxt assumptions. This is a forward-looking estimate, not a guarantee.
Material changes and operating developments
- Therapeutics revenue rose sharply due to the March 2020 Servier amendment; the company remains dependent on partner payments and has no therapeutic product revenue.
- R&D expense decreased 5.5% year over year, while cost of revenue increased to $36.3 million, largely reflecting Calyxt product costs and inventory and commodity-hedging effects.
- Capital spending and construction expanded substantially: additions to tangible and intangible assets were $50.6 million, versus $17.7 million in 2019. The Paris raw-material facility began production in 2020; Raleigh production was expected to start in 2021.
- Cellectis received an €18.5 million state-guaranteed loan during 2020. Calyxt raised $15.0 million gross in an October offering, including a $5.0 million Cellectis investment.
Outlook, risks and unusual items
- Management expected operating losses and expenses to continue as clinical programs, manufacturing capacity, and R&D advance. No quantitative revenue or earnings guidance was provided.
- COVID-19 could disrupt trial enrollment and follow-up, research, suppliers, manufacturing start-up, and financing. The company said trials continued during 2020 but expected pandemic-related impacts whose timing and scale were uncertain.
- The FDA placed the UCARTCS1 MELANI-01 study on hold in July 2020 following a patient’s fatal cardiac arrest after extensive prior treatment; the hold was lifted in November after protocol safety adjustments. Clinical safety, efficacy, and preliminary results remain uncertain.
- Preliminary UCART22 data involved five treated patients: two achieved complete remission with incomplete blood-count recovery at Day 28, with one later reaching complete remission. The filing cautions that early data are not statistically significant and may change.
- Cellectis reported patient deaths and serious toxicities in its and partners’ CAR T studies, including CRS, cytopenias, infections, and treatment-related deaths in UCART19 studies. Manufacturing scale-up, regulatory approval, patient recruitment, and collaborator execution remain material risks.
- Calyxt changed its go-to-market strategy, contracted to sell approximately four million bushels of 2020 high-oleic soybean production to ADM, and entered an alfalfa trait-license agreement. High-fiber wheat development was delayed by at least a year after an outside party’s improper chemical application during field trials.
- Foreign exchange contributed to a $12.0 million net financial loss in 2020, including a $13.9 million foreign-exchange loss. A French tax-authority audit of 2014–2017 research credits remained unresolved; management recorded no provision.
- Auditors issued unqualified opinions on the financial statements and internal controls. Management reported effective disclosure controls and internal control over financial reporting. The report also notes that the PCAOB had been unable to inspect the French audit firm under the then-current oversight arrangement.
Most important facts for investors to verify
- Reconcile the filing’s differing disclosures of deferred Servier revenue recognized in 2020 and assess how much of the revenue increase is nonrecurring.
- Track unrestricted liquidity, cash burn, capital spending, loan and lease obligations, and the assumptions behind the late-2022 funding estimate.
- Review updated safety, efficacy, enrollment, and regulatory status for AMELI-01, BALLI-01, MELANI-01, and partner-led programs.
- Confirm Raleigh facility start-up, manufacturing capacity and costs, and whether Calyxt’s new sales and licensing strategy can generate sustainable margins.
- Monitor the French research-tax-credit audit, foreign-exchange exposure, and any further COVID-19 or supply-chain effects.